Akero Therapeutics AKRO

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$1.55 (-3.55%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Akero Therapeutics (AKRO)
    Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $42.12

    • Market Cap

      $3.35 Billion

    • Price-Earnings Ratio

      -11.23

    • Total Outstanding Shares

      79.62 Million Shares

    • Total Employees

      63

    • Dividend

      No dividend

    • IPO Date

      June 20, 2019

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      601 gateway boulevard, suite 350, South san francisco, CA, 94080

    • Homepage

      https://www.akerotx.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$-230.11 Million
    Net Cash Flow, Continuing$106.03 Million
    Net Cash Flow From Financing Activities, Continuing$445.85 Million
    Net Cash Flow$106.03 Million
    Net Cash Flow From Investing Activities, Continuing$-109.71 Million
    Net Cash Flow From Investing Activities$-109.71 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Basic Earnings Per Share$-3.75
    Net Income/Loss Available To Common Stockholders, Basic$-252.06 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Preferred Stock Dividends And Other Adjustments$0
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Net Income/Loss Attributable To Parent$-252.06 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss$678,000
    Comprehensive Income/Loss Attributable To Parent$-251.38 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-251.38 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Current Liabilities$39.75 Million
    Liabilities And Equity$825.89 Million
    Equity Attributable To Noncontrolling Interest$0
    Noncurrent Liabilities$36.02 Million
    Equity$750.11 Million
    Noncurrent Assets$55.51 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AKRO from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.